Enteric NeuroScience Program and Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota; Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Department of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Enteric NeuroScience Program and Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota; Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Gastroenterology. 2023 Dec;165(6):1458-1474. doi: 10.1053/j.gastro.2023.08.009. Epub 2023 Aug 18.
BACKGROUND & AIMS: Although depletion of neuronal nitric oxide synthase (NOS1)-expressing neurons contributes to gastroparesis, stimulating nitrergic signaling is not an effective therapy. We investigated whether hypoxia-inducible factor 1α (HIF1A), which is activated by high O consumption in central neurons, is a Nos1 transcription factor in enteric neurons and whether stabilizing HIF1A reverses gastroparesis.
Mice with streptozotocin-induced diabetes, human and mouse tissues, NOS1 mouse neuroblastoma cells, and isolated nitrergic neurons were studied. Gastric emptying of solids and volumes were determined by breath test and single-photon emission computed tomography, respectively. Gene expression was analyzed by RNA-sequencing, microarrays, immunoblotting, and immunofluorescence. Epigenetic assays included chromatin immunoprecipitation sequencing (13 targets), chromosome conformation capture sequencing, and reporter assays. Mechanistic studies used Cre-mediated recombination, RNA interference, and clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9)-mediated epigenome editing.
HIF1A signaling from physiological intracellular hypoxia was active in mouse and human NOS1 myenteric neurons but reduced in diabetes. Deleting Hif1a in Nos1-expressing neurons reduced NOS1 protein by 50% to 92% and delayed gastric emptying of solids in female but not male mice. Stabilizing HIF1A with roxadustat (FG-4592), which is approved for human use, restored NOS1 and reversed gastroparesis in female diabetic mice. In nitrergic neurons, HIF1A up-regulated Nos1 transcription by binding and activating proximal and distal cis-regulatory elements, including newly discovered super-enhancers, facilitating RNA polymerase loading and pause-release, and by recruiting cohesin to loop anchors to alter chromosome topology.
Pharmacologic HIF1A stabilization is a novel, translatable approach to restoring nitrergic signaling and treating diabetic gastroparesis. The newly recognized effects of HIF1A on chromosome topology may provide insights into physioxia- and ischemia-related organ function.
尽管神经元型一氧化氮合酶(NOS1)表达神经元的耗竭导致胃轻瘫,但刺激氮能信号并非有效的治疗方法。我们研究了中枢神经元中高氧消耗激活的缺氧诱导因子 1α(HIF1A)是否为肠神经元中的 Nos1 转录因子,以及稳定 HIF1A 是否能逆转胃轻瘫。
使用链脲佐菌素诱导糖尿病的小鼠、人组织、NOS1 小鼠神经母细胞瘤细胞和分离的氮能神经元进行研究。通过呼吸测试和单光子发射计算机断层扫描分别确定固体和体积的胃排空。通过 RNA 测序、微阵列、免疫印迹和免疫荧光分析基因表达。表观遗传测定包括染色质免疫沉淀测序(13 个靶点)、染色体构象捕获测序和报告基因检测。机制研究使用 Cre 介导的重组、RNA 干扰和规律成簇间隔短回文重复(CRISPR)-CRISPR 相关蛋白 9(Cas9)介导的表观基因组编辑。
来自生理细胞内缺氧的 HIF1A 信号在小鼠和人 NOS1 肌间神经元中活跃,但在糖尿病中减少。在表达 Nos1 的神经元中删除 Hif1a 可使 NOS1 蛋白减少 50%至 92%,并延迟雌性而非雄性小鼠的固体胃排空。用罗沙司他(FG-4592)稳定 HIF1A(已被批准用于人类)可恢复 NOS1 并逆转雌性糖尿病小鼠的胃轻瘫。在氮能神经元中,HIF1A 通过结合并激活近端和远端顺式调控元件(包括新发现的超级增强子),促进 RNA 聚合酶加载和暂停释放,并招募黏合蛋白到环锚点来改变染色体拓扑结构,从而上调 Nos1 转录。
药物稳定 HIF1A 是恢复氮能信号和治疗糖尿病性胃轻瘫的一种新的、可转化的方法。HIF1A 对染色体拓扑结构的新作用可能为与缺氧和缺血相关的器官功能提供见解。